Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Consensus Target Price of $10.00 According to Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $10.00.

A number of analysts have recently issued reports on the stock. UBS Group reiterated a “buy” rating on shares of Autolus Therapeutics in a report on Wednesday. HC Wainwright restated a “buy” rating on shares of Autolus Therapeutics in a research note on Wednesday. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Finally, Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd.

View Our Latest Report on AUTL

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC bought a new position in shares of Autolus Therapeutics in the third quarter valued at about $28,000. Privium Fund Management B.V. lifted its position in Autolus Therapeutics by 29.2% during the third quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock worth $911,000 after acquiring an additional 106,060 shares during the last quarter. Vise Technologies Inc. acquired a new position in shares of Autolus Therapeutics in the third quarter valued at approximately $35,000. QRG Capital Management Inc. increased its stake in shares of Autolus Therapeutics by 67.7% during the second quarter. QRG Capital Management Inc. now owns 18,325 shares of the company’s stock worth $29,000 after purchasing an additional 7,400 shares during the period. Finally, Alphabet Inc. bought a new stake in Autolus Therapeutics in the 2nd quarter valued at $1,117,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock opened at $1.17 on Monday. The company has a debt-to-equity ratio of 5.25, a current ratio of 3.72 and a quick ratio of 3.36. The firm has a market cap of $311.62 million, a price-to-earnings ratio of -1.21 and a beta of 2.32. The stock’s 50-day moving average is $1.70 and its 200-day moving average is $1.66. Autolus Therapeutics has a one year low of $1.12 and a one year high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). The business had revenue of $41.24 million during the quarter, compared to the consensus estimate of $39.54 million. Autolus Therapeutics had a negative return on equity of 263.25% and a negative net margin of 186.37%. During the same period last year, the company earned ($0.30) earnings per share. Equities analysts predict that Autolus Therapeutics will post -0.75 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Featured Stories

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.